A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Dinutuximab (Primary) ; Carboplatin; Cell therapies; Cyclophosphamide; Etoposide; Granulocyte macrophage colony stimulating factor; Granulocyte-macrophage colony-stimulating factors; Ifosfamide; Interleukin-2; Irinotecan; Temozolomide; Topotecan
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms GD2NK
- 14 Nov 2018 Status changed from active, no longer recruiting to completed.
- 19 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Oct 2018.
- 22 Feb 2017 Planned End Date changed from 1 Sep 2019 to 1 Feb 2019.